Pub Date : 2023-11-01DOI: 10.21608/aijpms.2023.221239.1223
Ayah Khalil, Ahmed Mukhtar, Ahmed Lotfy, Karima Abu EL-Fotuh, Zeinab Zalat
: According to the product information for parenteral paracetamol, fewer than 1% of patients will have more severe adverse effects like hypotension. However, a number of studies suggest that the prevalence of hypotension caused by parenteral paracetamol may be higher than actually thought by the drug's producers. We carried out prospective, controlled, randomized research to compare the clinical implications of intravenous paracetamol bolus versus intravenous paracetamol extended infusion. The 61 adult septic shock patients were divided into three groups by randomization: Bolus group who received paracetamol 1g/100ml infused over 15 minutes, while the extended infusion group who received paracetamol 1g/100ml infused over three hours. The control group who received normal saline 100ml infused over 15 minutes. The main outcome was the incidence and prevalence of reduced blood pressure, which was detected by a systolic blood pressure drop of ≥ 20 ٪ from baseline. Mean arterial pressure, vasopressor infusion flow rate, and both diastolic and systolic blood pressure did not change significantly according to statistical analysis between the three groups at baseline, one, three, or six hours after the intervention. The incidence of hypotension was 19% (4 of 21 patients) within the control or normal saline group, 50% (10 of 20 patients) within the bolus group, and 35% (7 of 20) within the extended infusion group. The prevalence of hypotensive episodes was greater in the bolus group, even though there was no clinically meaningful difference between intravenous paracetamol prolonged infusion and bolus. We do not need to administer paracetamol as a prolonged infusion to prevent the hemodynamics parameter from being negatively impacted.
{"title":"The hypotension caused by intravenous paracetamol in septic shock patients: A single center placebo controlled randomized study","authors":"Ayah Khalil, Ahmed Mukhtar, Ahmed Lotfy, Karima Abu EL-Fotuh, Zeinab Zalat","doi":"10.21608/aijpms.2023.221239.1223","DOIUrl":"https://doi.org/10.21608/aijpms.2023.221239.1223","url":null,"abstract":": According to the product information for parenteral paracetamol, fewer than 1% of patients will have more severe adverse effects like hypotension. However, a number of studies suggest that the prevalence of hypotension caused by parenteral paracetamol may be higher than actually thought by the drug's producers. We carried out prospective, controlled, randomized research to compare the clinical implications of intravenous paracetamol bolus versus intravenous paracetamol extended infusion. The 61 adult septic shock patients were divided into three groups by randomization: Bolus group who received paracetamol 1g/100ml infused over 15 minutes, while the extended infusion group who received paracetamol 1g/100ml infused over three hours. The control group who received normal saline 100ml infused over 15 minutes. The main outcome was the incidence and prevalence of reduced blood pressure, which was detected by a systolic blood pressure drop of ≥ 20 ٪ from baseline. Mean arterial pressure, vasopressor infusion flow rate, and both diastolic and systolic blood pressure did not change significantly according to statistical analysis between the three groups at baseline, one, three, or six hours after the intervention. The incidence of hypotension was 19% (4 of 21 patients) within the control or normal saline group, 50% (10 of 20 patients) within the bolus group, and 35% (7 of 20) within the extended infusion group. The prevalence of hypotensive episodes was greater in the bolus group, even though there was no clinically meaningful difference between intravenous paracetamol prolonged infusion and bolus. We do not need to administer paracetamol as a prolonged infusion to prevent the hemodynamics parameter from being negatively impacted.","PeriodicalId":481938,"journal":{"name":"Azhar International Journal of Pharmaceutical and Medical Sciences (Print)","volume":"136 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135714783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-13DOI: 10.21608/aijpms.2023.203637.1207
Omneya Elbakry, Marwa Harras, Mohamed Elsebaei, Ahmed Mehany, Hend Elsehrawi
: It has been revealed that scaffolds made from pyrazolo[1,5-a]pyrimidines exhibit valuable biological activities, particularly anti-proliferative efficacy and blocking CDK activity. Therefore, new derivatives of pyrazolo[1,5-a]pyrimidines 5a-c were synthesized, and their chemical structures were validated using several spectral studies. These compounds were screened against MCF-7, HCT-116
{"title":"Development of pyrazolo[1,5-a]pyrimidine derivatives: Synthesis, anticancer activity and docking study","authors":"Omneya Elbakry, Marwa Harras, Mohamed Elsebaei, Ahmed Mehany, Hend Elsehrawi","doi":"10.21608/aijpms.2023.203637.1207","DOIUrl":"https://doi.org/10.21608/aijpms.2023.203637.1207","url":null,"abstract":": It has been revealed that scaffolds made from pyrazolo[1,5-a]pyrimidines exhibit valuable biological activities, particularly anti-proliferative efficacy and blocking CDK activity. Therefore, new derivatives of pyrazolo[1,5-a]pyrimidines 5a-c were synthesized, and their chemical structures were validated using several spectral studies. These compounds were screened against MCF-7, HCT-116","PeriodicalId":481938,"journal":{"name":"Azhar International Journal of Pharmaceutical and Medical Sciences (Print)","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135786498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-08DOI: 10.21608/aijpms.2023.191741.1192
zeinab Hussein, Afaf Ramadan, shereen eladawy
: Designing an effective intranasal (IN) delivery mechanism for the water-soluble anti-epileptic drug levetiracetam (LEV) for brain targeting effect was the main objective of this work. By using the nanoprecipitation process and the polymer Eudragit S100, nanospheres were prepared. Different weights of Eudragit S100 and varied concentrations of poloxamer 188 (stabilizer) were employed. The produced levetiracetam nanospheres exhibited sufficient entrapment efficiency range from 79.2% to 93.5%, with zeta potential values from 26.7 mV to 40.6 mV. The developed Nanospheres had spherical shape and nanosize range (10.44 to 79.07 nm). In situ gels prepared from Poloxamer 407 (18%) and different mucoadhesive polymers (sodium carboxymethylcellulose (Na CMC) and chitosan) were evaluated for gelling time, gelling temperature, pH and rheology. The nanosphere in situ gels were further evaluated for in vitro drug release and revealed 73.6% to 84.5% release within 8 hrs. The optimum in situ gel formula, based on rank of rheology and % release after 8 hrs, was evaluated for stability, and evaluated for ex-vivo permeation through nasal mucosa.
{"title":"Brain Targeted Delivery of Levetiracetam Loaded Nanosphere","authors":"zeinab Hussein, Afaf Ramadan, shereen eladawy","doi":"10.21608/aijpms.2023.191741.1192","DOIUrl":"https://doi.org/10.21608/aijpms.2023.191741.1192","url":null,"abstract":": Designing an effective intranasal (IN) delivery mechanism for the water-soluble anti-epileptic drug levetiracetam (LEV) for brain targeting effect was the main objective of this work. By using the nanoprecipitation process and the polymer Eudragit S100, nanospheres were prepared. Different weights of Eudragit S100 and varied concentrations of poloxamer 188 (stabilizer) were employed. The produced levetiracetam nanospheres exhibited sufficient entrapment efficiency range from 79.2% to 93.5%, with zeta potential values from 26.7 mV to 40.6 mV. The developed Nanospheres had spherical shape and nanosize range (10.44 to 79.07 nm). In situ gels prepared from Poloxamer 407 (18%) and different mucoadhesive polymers (sodium carboxymethylcellulose (Na CMC) and chitosan) were evaluated for gelling time, gelling temperature, pH and rheology. The nanosphere in situ gels were further evaluated for in vitro drug release and revealed 73.6% to 84.5% release within 8 hrs. The optimum in situ gel formula, based on rank of rheology and % release after 8 hrs, was evaluated for stability, and evaluated for ex-vivo permeation through nasal mucosa.","PeriodicalId":481938,"journal":{"name":"Azhar International Journal of Pharmaceutical and Medical Sciences (Print)","volume":"53 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136362312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：